Get the Stockscreener App
1.32
0.00%
0.00
After Hours:
1.33
0.01
+0.76%
Repare Therapeutics Inc stock is traded at $1.32, with a volume of 1.09M.
It is up +0.00% in the last 24 hours and down -53.52% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
1.09M
Relative Volume:
3.78
Market Cap:
$56.11M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-8.80
EPS:
-0.15
Net Cash Flow:
$-129.10M
1W Performance:
-25.42%
1M Performance:
-53.52%
6M Performance:
-62.50%
1Y Performance:
-79.66%
1-Day Range:
$1.30
$1.45
1-Week Range:
$1.225
$1.83
52-Week Range:
$1.225
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.32 | 56.11M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance
Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com
Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Promising trial results for Repare's cancer drug combo - Investing.com India
Repare stock tanks 38% after Phase 1 data release - MSN
Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
Repare Therapeutics' Cancer Drug Combo Shows Strong 37.5% Response Rate in Advanced Ovarian Cancer Trial - StockTitan
Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - BioSpace
UK desirability has turned a corner in clinical trials - Yahoo Finance
Repare Therapeutics to Present Phase 1 Cancer Trial Data for Novel Drug Combination in December - StockTitan
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance
Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia
Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
Repare Therapeutics partners with NCI on cancer drug - Investing.com India
Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan
Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo Finance
Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance
Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace
Repare Therapeutics reports progress in cancer trial - Investing.com India
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN
Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News
Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices
Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Apr 01 '24 |
Sale |
4.63 |
2,491 |
11,533 |
107,558 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Sale |
4.62 |
825 |
3,812 |
45,564 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Sale |
4.61 |
789 |
3,637 |
44,775 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Sale |
4.64 |
450 |
2,088 |
72,318 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Apr 01 '24 |
Sale |
4.66 |
410 |
1,911 |
71,908 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Mar 28 '24 |
Sale |
4.64 |
500 |
2,320 |
231,709 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Apr 01 '24 |
Sale |
4.66 |
300 |
1,398 |
231,409 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '24 |
Sale |
4.79 |
825 |
3,952 |
43,862 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 27 '24 |
Sale |
4.62 |
825 |
3,812 |
42,212 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '24 |
Sale |
4.60 |
825 |
3,795 |
43,037 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):